TNXP - .64 Pre-market now at .8701/.886 Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting https://stockcharts.com/c-sc/sc?s=TNXP&p=D&b=5&g=0&i=t63447239276&r=1540986386158